COMMENTARY

Pharma’s Downsizing Bandwagon Shows No Sign of Slowing, Companies Seeking Even Leaner Staff

By Reiji Anasako October 28, 2019
Drug makers’ downsizing moves continue unabated in Japan. In the past three months alone, it was revealed that voluntary redundancy programs were being planned or launched for Pfizer, MSD, and Sanofi, affecting a total of over 600 staffers mainly in…

To read the full story

COMMENTARY

By Takashi Ebisawa

Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…

A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…

By Reiji Anasako

Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…